Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2014

Atefi Mohammad, Avramis Earl, Lassen Amanda, Wong Deborah J L, Robert Lidia, Foulad David, Cerniglia Michael, Titz Bjoern, Chodon Thinle, Graeber Thomas G, Comin-Anduix Begonya, Ribas Antoni

Abstract excerpt

PURPOSE: PD-L1 is the main ligand for the immune inhibitory receptor PD-1. This ligand is frequently expressed by melanoma cells. In this study, we investigated whether PD-L1 expression is controlled by melanoma driver mutations and modified by oncogenic signaling inhibition. EXPERIMENTAL DESIGN: Expression of PD-L1 was investigated in a panel of 51 melanoma cell lines containing different oncogenic mutations,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Coculture Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Lymphocytes

Share to Mitogen-Activated Protein Kinases

Share to Phosphatidylinositol 3-Kinases

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 24812408
DOI: 10.1158/1078-0432.CCR-13-2797
PMCID: PMC4079734

Genes

BRAF
NRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.PMID 24812408Read ↗

PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.Semantic proximity Read ↗

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.Semantic proximity Read ↗

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint InhibitorsSemantic proximity Read ↗

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.Semantic proximity Read ↗

PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5pSemantic proximity Read ↗

Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.Semantic proximity Read ↗

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in MelanomaSemantic proximity Read ↗

Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?Semantic proximity Read ↗

Recent Findings in the Regulation of Programmed Death Ligand 1 ExpressionSemantic proximity Read ↗

MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.Semantic proximity Read ↗

Programmed Cell Death Ligand 1 Immunohistochemical Expression and Cutaneous Melanoma: A Controversial RelationshipSemantic proximity Read ↗

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.